The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease

British Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2000, Pages 417-421

  Glue, Paul ^a   Schenker, Steven ^a   Gupta, Samir ^b   Clement, Robert P ^a   Zambas, Demetris ^a   Salfi, Margaret ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Liver disease; Pharmacokinetics; Ribavirin

Indexed keywords

RIBAVIRIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; KIDNEY CLEARANCE; LIVER FUNCTION; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; CHRONIC DISEASE; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 0034106861     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00186.x     Document Type: Article

References (20)

1. Fernandez H, Danks G, Smith R. Ribavirin: a clinical overview. EtirJ Epideniiol 1986; 2: 1-14.
2. Sidwell R, HofFman J, Kharp L, et al. Broad spectrum antiviral activity of virazole: l-beta-D-riboruranosyl-l,2,4-triazole3-carboxamide. Science 1972; 117: 705-706.
3. Sidwell RW, Robins RK, Hillyard IW. Ribavirin: an antiviral agent. Phannacol Tlicr 1979; 6: 123-146.
4. Di Bisceglie AM, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. Ann Int Meet 1995; 123: 897-903.
5. Davis GL, Estaban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N EnglJ Med 1998; 339: 1493-1499.
6. McHutchison JG, Gordon SC, Schiff ER, er al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N EnglJ Med 1998; 339: 1485-1492.
7. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon a-2b plus ribavirin for 48 weeks or 24 weeks versus interferon a-2b plus placebo for 48 weeks the treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
8. Reichard O, Norkrans G, Fryden A, et al. Randomized double-blind placebo-controlled study of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
9. Paroni R, Del Puppo M, Borghi C, et al. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Phannacol Tlier Toxicol 1989; 27: 302-307.
10. Laskin ÖL, Longstreth JA, Hart ÇA, et al. Ribavirin disposition in high risk patients for acquired immunodeficiency syndrome. Clin Phannacol Tlier 1987; 41: 546-555.
11. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alpha-2b in chronic hepatitis C. assessment of possible pharmacokinetic and pharmacodynamic interactions. BrJ Clin Phannacol 1998; 46: 563-570.
12. Pugh R, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. BrJ Surg 1973; 60: 646-649.
13. Child CG. Tlie liver and portal hypertension. Saunders, Philadelphia, 1964.
14. Gibaldi M, Perrier D. Pliannacokinetics, 2nd edn. New York. Marcel Dekker, 1982: 409-417.
15. 14C-ribavirin distribution and pharmacokinetic studies in rats, baboons and man. In Ribavirin: a Broad Spectrum Antiviral Agent, eds Smith RA, Kirkpatrick W. New York: Academic Press, 1980. pp 83-98.
16. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin using stable-label isotope methodology in normal volunteers. Antimicrob Agents Chemother 1999; 43: 2451-2456.
17. Lertora_UL, Rege AB, Lacour JT, el at. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Phannacol Tlier 1991; 50: 442-449.
18. Branch RA. Drugs in liver disease. Clin Phannacol Tlier 1998; 64: 462-465.
19. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease, din Phannacokinet 1991; 21: 42-69.
20. Glue P. The clinical pharmacology of ribavirin. Sem Liv Dis 1999; 19(Suppl 1) 17-24.